% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Kunte:276155,
      author       = {Kunte, Sophie C and Wenter, Vera and Toms, Johannes and
                      Lindner, Simon and Unterrainer, Marcus and Eilsberger,
                      Friederike and Jurkschat, Klaus and Wängler, Carmen and
                      Wängler, Björn and Schirrmacher, Ralf and Tiling,
                      Maximilian W and Sheikh, Gabriel T and Mehrens, Dirk and
                      Brendel, Matthias and Rübenthaler, Johannes and
                      Auernhammer, Christoph J and Spitzweg, Christine and
                      Unterrainer, Lena M and Holzgreve, Adrien},
      title        = {{PET}/{CT} imaging of differentiated and medullary thyroid
                      carcinoma using the novel {SSTR}-targeting peptide
                      [18{F}]{S}i{TATE} - first clinical experiences.},
      journal      = {European journal of nuclear medicine and molecular imaging},
      volume       = {52},
      number       = {3},
      issn         = {1619-7070},
      address      = {Heidelberg [u.a.]},
      publisher    = {Springer-Verl.},
      reportid     = {DZNE-2025-00227},
      pages        = {900 - 912},
      year         = {2025},
      abstract     = {The novel 18F-labeled somatostatin receptor (SSTR)-directed
                      radiotracer [18F]SiTATE demonstrated promising results for
                      the imaging of various SSTR-expressing tumor types. Although
                      thyroid carcinomas (TC) express SSTR, data on [18F]SiTATE
                      PET/CT imaging in TC are lacking. This study explores the
                      use of [18F]SiTATE PET/CT in a patient cohort with
                      histologically proven TC.As part of a prospective
                      observational study at a single tertiary cancer center, 21
                      patients with TC (10 medullary (MTC) and 11 differentiated
                      (DTC)) who underwent at least one [18F]SiTATE PET/CT were
                      included (37 scans in total). Mean SUVmax and SUVmean of
                      tumoral lesions, mean total-tumor-volume (TTV), and
                      whole-body (WB)-SUVmax and WB-SUVmean on PET with their
                      standard deviations (SDs) were determined. PET parameters
                      were correlated to clinical parameters including tumor
                      marker levels (thyroglobulin for DTC, calcitonin for MTC).89
                      lesions were included in the analysis. Metastases were
                      localized in the bone, lymph nodes, lung, soft tissue, and
                      thyroid bed. Osseous (31 lesions; SUVmax 8.6 ± 8.0; SUVmean
                      5.8 ± 5.4) and nodal (37 lesions; SUVmax 8.7 ± 7.8;
                      SUVmean 5.7 ± 5.4) metastases showed the highest uptake.
                      The MTC disease burden on PET significantly correlated with
                      the calcitonin tumor marker level (e.g., TTV: r = 0.771, r2
                      = 0.594, p = 0.002). For DTC, no such correlation was
                      present.Our data demonstrate high feasibility of [18F]SiTATE
                      PET/CT in a small cohort of patients with MTC and DTC. The
                      use of [18F]SiTATE may overcome logistical disadvantages of
                      68Ga-based tracers and facilitate SSTR-targeted PET/CT
                      imaging of thyroid carcinoma.},
      keywords     = {Humans / Thyroid Neoplasms: diagnostic imaging / Thyroid
                      Neoplasms: metabolism / Male / Female / Positron Emission
                      Tomography Computed Tomography / Middle Aged / Carcinoma,
                      Neuroendocrine: diagnostic imaging / Receptors,
                      Somatostatin: metabolism / Adult / Aged / Fluorine
                      Radioisotopes / (4–6): Medullary thyroid carcinoma (MTC)
                      (Other) / Differentiated thyroid carcinoma (DTC) (Other) /
                      Follicular thyroid carcinoma (FTC) (Other) / Papillary
                      thyroid carcinoma (PTC) (Other) / Serum tumor marker (Other)
                      / Somatostatin receptor (SSTR) (Other) / Receptors,
                      Somatostatin (NLM Chemicals) / Fluorine Radioisotopes (NLM
                      Chemicals)},
      cin          = {AG Haass},
      ddc          = {610},
      cid          = {I:(DE-2719)1110007},
      pnm          = {352 - Disease Mechanisms (POF4-352)},
      pid          = {G:(DE-HGF)POF4-352},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:39404789},
      doi          = {10.1007/s00259-024-06944-y},
      url          = {https://pub.dzne.de/record/276155},
}